C.S. Mott Children’s Hospital provides comprehensive care for children, adolescents and young adults with all forms of childhood cancer, including offering specialized expertise in rare and resistant brain cancers.
At C.S. Mott Children’s Hospital, your child will have the benefit of an individualized treatment plan developed by a team of specialists in pediatric neurosurgery, pediatric radiation therapy, pediatric oncology and pediatric neuro-oncology, pediatric endocrinology, ophthalmology and pediatric otolaryngology, working hand-in-hand to optimize your child’s care and apply the very latest therapies available.
The pediatric neurosurgery team, led by Hugh Garton, M.D., uses Intraoperative MRI technology to provide a detailed view of brain tumors during surgery, further enhancing the precision of our experienced neurosurgical team.
Our precision oncology program offers the most comprehensive DNA and RNA sequencing capabilities available, guiding each patient’s medical team in the creation of individualized treatment recommendations based on the biologic profile of each patient’s tumor vs. relying on one-size-fits-all therapies using agents designed for adult brain tumors.
The Brain Tumor (CNS) Tumor Precision Medicine Conference is held monthly with the goal of identifying precision-medicine based therapies for pediatric brain tumor patients using molecular info generated from innovative research and clinical tests performed at the University of Michigan. Patient cases are reviewed at each meeting, including pathology results, clinical molecular results, clinical cytogenetics results, Mi-Oncoseq tumor genomic profiling, and information from tumor samples obtained and/or cultured through U-M Brain Tumor Tissue Bank Program.
Each case is discussed with a focus on potential treatment implications, with a multi-disciplinary team including neuro-pathology, pathology/cytogenetics, pharmacology, and research team members. This conference is also tele-conferenced with clinicians/researchers at multiple leading children’s hospitals nationally. Protected health information from cases is removed to respect the privacy of each patient.
C.S. Mott Children’s Hospital offers access to a large pipeline of experimental therapies through our active membership in the Children's Oncology Group Phase I and Phase II-III consortiums. As one of only 20 institutions nationwide able to offer Phase 1 clinical trials to our patients, U-M has the most comprehensive and largest portfolio of clinical trials in the state of Michigan for brain tumors, including many which were developed here at U-M.